DNA minor groove at guanine N2

The DNA minor groove at the guanine N2 position is a specialized pharmacological target for a class of alkylating agents and minor groove binders that exhibit unique anti-tumor properties. Unlike traditional alkylators that often target the N7 or O6 positions of guanine in the major groove, drugs targeting the N2 position in the minor groove, such as trabectedin and lurbinectedin, form covalent adducts that bend the DNA molecule toward the major groove (D'Incalci & Galmarini, 2010). This specific structural distortion interferes with the binding of various transcription factors and disrupts the activity of the transcription-coupled nucleotide excision repair (TC-NER) system (Soares et al., 2007). In a mechanism distinct from other DNA-damaging agents, the interaction between these adducts and the NER machinery leads to the generation of lethal double-strand breaks rather than successful repair, particularly in cells with high transcriptional activity. This target is of significant clinical interest in the treatment of soft tissue sarcomas, ovarian cancer, and small cell lung cancer (Zepzelca FDA Label). The efficacy of drugs hitting this target is highly dependent on the cellular expression of DNA repair proteins like ERCC1 and XPG, which serve as potential biomarkers for patient response.

Other names

Guanine N2 positionDNA minor groove guanine adduct siteN2-guanine DNA adductMinor groove guanine amino group

Covalent alkylation of the N2 amino group of guanine in the DNA minor groove, leading to DNA bending, inhibition of transcription factor binding, and induction of DNA double-strand breaks via interference with the transcription-coupled nucleotide excision repair (TC-NER) pathway (D'Incalci & Galmarini, 2010; Soares et al., 2007).